Licenseable Technologies

Baycrest’s “My Virtual Dream” brain exhibit at Ontario Science Centre Jan 17-18, 2015

MaRS Innovation is a My Virtual Dream event sponsor and commercialization partner

Baycrest Logo 2015Toronto, ON (January 12, 2015) – Baycrest Health Sciences’ dazzling brain science exhibit from 2013 Scotiabank Nuit Blanche will be on show at the Ontario Science Centre’s BRAINFest, Jan. 17-18.

My Virtual Dream is an innovative and interactive live performance experience at the intersection of science, art and music.  The installation will enable participants to use their brain waves to communicate with each other through an immersive audio and visual expression that will be projected onto video screens.

“Participating at BRAINFest is a great way to share Baycrest’s renowned strengths in cognitive neuroscience in a highly artistic and interactive way with the public,” says Dr. Randy McIntosh, vice-president of Research and Director of Baycrest’s Rotman Research Institute. “Baycrest wishes to thank the Ontario Brain Institute for bringing My Virtual Dream into the Ontario Science Centre and to MaRS Innovation as our key collaborative partner.”

The concept for My Virtual Dream is inspired by an ongoing international project led by Dr. McIntosh and the Rotman to build a virtual, functional brain – a research and diagnostic tool that could one day revolutionize brain healthcare.

The installation, created by Baycrest and the University of Toronto for Nuit Blanche 2013, was a huge hit with fans of the festival. It also represented an extraordinary neuroscience experiment that explored how people can collectively synchronize their brain waves to co-create a multi-sensory environment that merges art, science and technology. In a single night, Rotman researchers collected brain data from over 500 people who signed on to be research subjects.

Continue Reading

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.

Here are our picks for the top 10 news stories from MaRS Innovation’s portfolio.

Triphase-logo-Web1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study to evaluate marizomib in Glioblastoma (GBM) with Celgene, signed an agreement to provide Celgene with an option to acquire a new bi-specific antibody (licensed by Triphase from PharmAbcine) and closed the year by announcing that Triphase’s proteasome inhibitor, marizomib, demonstrates potent synergistic anti-multiple myeloma activity in combination with pomalidomide.

Flybits Corporate Logo2. Flybits Inc., spun out of Ryerson University, announced a $3.75 million Series A financing with Robert Bosch Venture Capital to advance its context-aware mobile experience platform. The company was also named a Red Herring Top 100 North America winner.

XLV Diagnostics Inc. 3. XLV Diagnostics Inc., spun out from Sunnybrook Health Sciences Centre and the Thunder Bay Regional Research Institute, secured a $3 million Series A investment round with Boston-based Bernard M. Gordon Unitrust. XLV’s product will provide mammography image quality equivalent to top-of-the-line mammography machines currently in use, and will do so at a fraction of the cost of current generation systems. The funding will support continued product development and regulatory approval.

Continue Reading

Holland Bloorview’s Anxiety Meter included in Globe and Mail’s neuroscience feature

Holland Bloorview Kids Rehab“Research labs across Ontario are full of ingenious – and even life-saving – inventions. Unfortunately, many of them never make it to market,” writes Wendy Leung in “These six great neuroscience ideas could make the leap from lab to market” in the November 20, 2014 edition of the Globe and Mail.

MaRS Innovation, which was created to help researchers solve exactly this problem, has a project with Holland Bloorview Kids Rehabilitation Hospital that was featured in Leung’s article. Asim Siddiqi founded the anxiety meter app for children with autism.

Siddiqi recently competed in the Ontario Brain Institute’s OBI Entrepreneurs Program, funded in part by the Ontario Centres of Excellence.

Here’s an excerpt:

As much as 80 per cent of children with autism suffer from anxiety, but they often have trouble recognizing and communicating their anxiety states, Siddiqi explains. “Just like we sometimes have difficulty ourselves recognizing when we’re kind of stress-eating and things like that, they have it a little worse than we do.”

Using sensors on the body, Dymaxia’s anxiety meter picks up physiological signals, such as heart rate and skin conductance – or the amount of electric current that passes through sensors on the skin, which increases with stress and body temperature. It then processes those signals and provides feedback of the child’s anxiety state in real time on a mobile phone or tablet.

Continue Reading

BioPrinter engineering team wins Canada Dyson Award

This story appears courtesy of our colleagues at U of T Engineering News.

The printer was developed by (clockwise from top right) University of Toronto students Arianna Mcallister and Lian Leng; former student Boyang Zhang and University of Toronto associate professor Axel Guenther. (Photo courtesy of the James Dyson Foundation)
The printer was developed by (clockwise from top right) University of Toronto students Arianna Mcallister and Lian Leng; former student Boyang Zhang and University of Toronto associate professor Axel Guenther. (Photo courtesy of the James Dyson Foundation)

While some of us are using the new power of 3D printers to make smartphone cases and chocolate figurines, two engineering students from the University of Toronto are using them to print functional human skin.

On September 18, Arianna McAllister and Lian Leng were named the Canadian winners of the 2014 James Dyson Award for their invention, the PrintAlive Bioprinter.

This story was covered by CBC News and BBC News. The BioPrinter team is working with MaRS Innovation to commercialize their technology; read the news archive.

This 3D skin printer won four U of T engineers a $3,500 Canada James Dyson Award and a chance to compete for a $60,000 international prize (photo courtesy of PrintAlive and U of T news).
This 3D skin printer won four U of T engineers a $3,500 Canada James Dyson Award and a chance to compete for a $60,000 international prize (photo courtesy of PrintAlive and U of T news).

The machine – created in collaboration with Professor Axel Guenther, alumnus Boyang Zhang and Dr. Marc Jeschke, head of Sunnybrook Hospital’s Ross Tilley Burn Centre – prints large, continuous layers of tissue that recreate natural skin.

Continue Reading

WaveCheck campaign part of new study on crowdfunding medical research

MI’s Fazila Seker also interviewed in National Post article on what prompts medical researchers to consider crowdfunding

WavecheckThe WaveCheck crowdfunding campaign, which raised $53,390 on Indiegogo to support clinical trials for a clinical technique invented by researchers at Sunnybrook Health Sciences Centre and Ryerson University, was included in a new Canadian-led study on the merits of crowdfunding to support cancer and rare diseases.

“Crowdfunding drug development: The state of play in oncology and rare diseases,” was published in Drug Discovery Today‘s June issue.

MaRS Innovation has confirmed with lead author Professor Nick Dragojlovic of the University of British Columbia that WaveCheck was among the campaigns included in the study.

Continue Reading

U of T researchers demonstrate new class of solar-sensitive nanoparticle

University of TorontoNew research emerging from the University of Toronto’s Edward S Rogers Sr. Department of Electrical and Computer Engineering is developing and demonstrating a new class of solar-sensitive nanoparticle.

MaRS Innovation is working with Professor Ted Sargent, his research team and U of T’s Innovations and Partnerships Office (IPO) to incubate and commercialize this and other solar technologies. Their work was recently published in Nature Materials.

The paper’s publication was widely covered in the technical trades, including CNET.com, Tech Times, Compound Semiconductor.net and Gizmag, among others, and on the university’s website.

Here’s an excerpt from power-technology.com:

Led by post-doctoral researcher Zhijun Ning and Professor Ted Sargent, the research work resulted in the development of a new form of solid, stable light-sensitive nanoparticles, known as colloidal quantum dots.

Developed in collaboration with Dalhousie University, King Abdullah University of Science and Technology and Huazhong University of Science and Technology, the solar-sensitive nanoparticles are cheaper than the traditional panels, large and rectangular.

In addition to being cheaper, the colloidal quantum dots are more flexible solar cells, and better gas sensors, infrared lasers, infrared light emitting diodes and more.

Continue Reading

WaveCheck breast cancer technology receives $100,000

OICR’s catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May

WavecheckTORONTO, April 8, 2014 — People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).

The funding builds upon MaRS Innovation‘s Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last fall.

Read Jane Gerster’s article for the Toronto Star about OICR’s catalyst grant for WaveCheck. This announcement was also covered in Metro, BetaKit and Council of Academic Hospitals of Ontario’s Catalyst newsletter.

WaveCheck, a clinical technique invented, refined and tested by scientists at Sunnybrook Health Sciences Centre and Ryerson University over 20 years, aims to show whether chemotherapy is actually destroying a breast cancer tumour at the beginning of chemotherapy treatment (in as little as four weeks), rather than at the end of treatment (typically four to six months).

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. As of March 2015, Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, the non-invasive, image-guided technology has shown promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

“This is a significant step towards achieving the goal of personalized medicine. The clinical trials will confirm that information provided by WaveCheck can determine if the treatment is the appropriate one or that other options should be chosen, sparing patients the side effects of treatments that will not likely be successful,” said Dr. Tom Hudson, OICR’s president and scientific director. “If successful, WaveCheck could become a standard tool in the cancer treatment of the future.”

Continue Reading

WaveCheck Indiegogo campaign co-directors featured in MedCity News article

wave
MI’s Fazila Seker and Elizabeth Monier-Williams, campaign co-directors for WaveCheck, were featured in a MedCity News article about successfully crowdfunding in the healthcare field.

MaRS Innovation’s Dr. Fazila Seker and Elizabeth Monier-Williams spoke with Deanna Pogorelc of MedCity News about how to define success for campaigns crowdfunding for technologies and research related to the medical field.

The article, in MedCity News‘ Hot Topics section, questions whether a crowdfunding campaign needs to reach its funding goal to be deemed successful.

Seker and Monier-Williams completed an Indiegogo crowdfunding campaign in December for WaveCheck, a clinical technique developed to let women and men know if their breast cancer chemotherapy is working within weeks of beginning treatment instead of months later when treatment has already ended.

Here’s an excerpt from the article:

Fazila Seker, the director of technology and venture development at commercialization agency MaRS Innovation, said that one of the trickiest things about the crowdfunding industry is the notion that these platforms have an established crowd that’s lurking around looking for the next best thing.

“You can’t rely entirely on that,” she said. “You need to go out there and do your research and create your own following.”

Continue Reading

Council of Academic Hospitals features WaveCheck technology and crowdfunding campaign

waveThe Council of Academic Hospitals of Ontario’s online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology’s ability to effectively monitor chemotherapy response.

WaveCheck’s technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at the end of treatment (typically four to six months).

Here’s an excerpt from the article:

Breast cancer is the most common cancer among Canadian women, excluding non-melanoma skin cancers. It is the second leading cause of death from cancer in women in this country. The Canadian Cancer Society estimated that, in 2013, 65 Canadian women would be diagnosed with breast cancer every day, totaling 23,800 women a year; and 14 Canadian women would die from breast cancer every day, totaling 5,000 women a year. According to the Canadian Breast Cancer Foundation, one in nine Canadian women is expected to develop breast cancer during her lifetime; one in 29 will die from it.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top